Compound 1416Alternative Names: Compound 1416
Latest Information Update: 01 Jul 2016
At a glance
- Originator Nanjing University
- Developer Nanjing EffecttPharm Drug Development Corporation
- Class Antineoplastics
- Mechanism of Action P-glycoprotein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 01 Jul 2016 Clinical trials in Cancer (Adjunctive treatment) in China (unspecified route)